Thursday, 09 February 2023

 

 

LATEST NEWS Member Parliament meets Lt Governor Manoj Sinha DC Jammu Avny Lavasa listens to public grievances at Kharabali IIM Jammu, Deakin University hosts 2- day International Conference on “Reimagining Marketing with Technology” Training cum Orientation Programme on “Holistic Agriculture Development Plan” begins at Sheikh-ul-Alam Hall Budgam Preparations regarding celebrations of Mehraj-ul-Alam, Maha Shivratri festivals reviewed at Budgam DDC Kupwara Dr. Doifode Sagar Dattatray reviews progress of various developmental projects Training Cum Orientation Prog under "Holistic Development of Agriculture and allied sectors” held at Lalmandi Srinagar H&H Deptt Baramulla organises one-day Exhibition cum Awareness Camp for Cooperatives at Dak Bungalow DC Shopian Sachin Kumar Vaishya Visits Keller DC Ganderbal holds weekly Block Diwas at Panchayat Ghar Theeru Weekly Block Diwas : DC Udhampur Krittika Jyotsna holds public outreach programme at Chanunta DC Kishtwar Dr. Devansh Yadav presides over Weekly Block Diwas programme at Chamoti Drabshalla PIB Srinagar organises Media Workshop “Vartalap” at Ganderbal ADC Kulgam Viqar Ahmed Giri reviews arrangements for Shab-e-Mehraj, Maha Shivratri festivals Block Diwas has become an important driver of Responsive Governance : Dr Basharat Qayoom DC Kulgam Dr. Bilal Mohi-Ud-Din Bhat visits Waltengoo Administrative Complex, Sports Stadium to come up at Aloosa : Dr Owais Ahmad DDC Chairperson Kulgam Mohammad Afzal Parry Visited Kund DC Srinagar Mohammad Aijaz Asad holds Public Grievance Redressal Camp at Lasjan “Kali Jotta”Running Successfully, The endless words of appreciation Sab Fadey Jaange Trailer: Harish Verma & Hashneen Chauhan’s Upcoming Film Is Filled With Intense Thrill

 

New gene therapy may reduce bleeding risk for haemophilia patients

Health, Study, London, Research, Researchers, World News, New Gene Therapy

Web Admin

Web Admin

5 Dariya News

London , 24 Jul 2022

A team of researchers, led by those of Indian-origin, has in a breakthrough developed a single gene therapy injection that could dramatically reduce the bleeding risk faced by people with haemophilia B.

Haemophilia B is a rare and inherited genetic bleeding disorder caused by low levels of the factor IX (FIX) protein, needed for forming blood clots that help prevent or stop bleeding.

The gene responsible for making FIX protein is located on the X chromosome, so the severe form of haemophilia B is much more common in men.

Currently, patients with haemophilia B need to inject themselves regularly usually weekly with recombinant FIX, that is, regular replacement therapy to prevent excessive bleeding. Despite advances in treatment, patients may continue to see debilitating joint damage.

But the new type of adeno-associated virus (AAV) gene therapy candidate called FLT180a, developed by researchers from University College London treats severe and moderately severe cases of the condition.

The study, published in the New England Journal of Medicine, showed that one-time treatment with FLT180a led to sustained production of FIX protein from the liver in nine of 10 patients across four different dose levels, removing the need for regular replacement therapy.

"Removing the need for haemophilia patients to regularly inject themselves with the missing protein is an important step in improving their quality of life," said lead author Professor Pratima Chowdary, Royal Free Hospital at UCL Cancer Institute.

AAV gene therapy works by using a packaging from the proteins found in the outer coat of the virus, to deliver a functional copy of a gene directly to patient tissues to compensate for one that is not working properly.

Newly synthesised proteins are released into the blood and a one-time infusion can achieve long-lasting effects.Patients needed to take immunosuppressive drugs over several weeks to several months to prevent their immune systems from rejecting the therapy.

While the treatment was generally well tolerated, all patients experienced some form of adverse events, with an abnormal blood clot in one who received the highest FLT180a dose and had the highest levels of FIX protein.

In nine out of the 10 patients, the treatment led to a sustained increase in FIX protein production, which led to a decrease in excessive bleeding. They also no longer required weekly injections of FIX protein.

After 26 weeks, five patients had normal levels of FIX protein, three had low but increased levels, and one patient treated at the highest dose had an abnormally high level.

 

Tags: Health , Study , London , Research , Researchers , World News , New Gene Therapy

 

 

related news

 

 

 

Photo Gallery

 

 

Video Gallery

 

 

5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2023 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD